Key result
In elderly patients with NVAF, anticoagulation was associated with fewer thrombotic events (6.99% vs 10.98%) but more bleeding events (20.98% vs 12.72%) compared to no anticoagulation.
Why the study?
It was uncertain whether anticoagulation is safe for frail and non-frail elderly patients with nonvalvular atrial fibrillation.
Does anticoagulant therapy reduce thrombotic events and is it safe in frail and non-frail elderly patients with nonvalvular atrial fibrillation?
Population
361 elderly patients (aged ≥ 75 y) with NVAF
Comparison
Anticoagulation vs no anticoagulation, stratified by frailty status
Design
Cohort study
Follow-up
12 months
Authors
Loading...
Anticoagulation safety in frail elderly with NVAF requires individualized assessment; leaves open confirmation in randomized trials before practice change.
Cohort (n=361)
Does anticoagulant therapy reduce thrombotic events and is it safe in frail and non-frail elderly patients with nonvalvular atrial fibrillation?
Absolute Event Rate: 6.99% vs 10.98%
In elderly patients (≥75 years) with nonvalvular atrial fibrillation, anticoagulation reduces thrombotic events but increases overall bleeding, while major bleeding risk remains comparable, emphasizing the need for individualized assessment, particularly in frail patients.
Ding et al. (2024) conducted a cohort in nonvalvular atrial fibrillation (NVAF) (n=361). Anticoagulant therapy vs. No anticoagulation was evaluated on thrombotic events. In elderly patients with NVAF, anticoagulation was associated with fewer thrombotic events (6.99% vs 10.98%) but more bleeding events (20.98% vs 12.72%) compared to no anticoagulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: